Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients (NCT06408935)

🧪 Interventions in This Study

• Guselkumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (84 Sites)

Showing the first 25 of 84 sites.

• Center for Colitis and Crohns Disease University of California — San Francisco, California
• The University of Chicago Medical Center (UCMC) — Chicago, Illinois
• Washington University School Of Medicine — St Louis, Missouri
• Medical University of South Carolina — Charleston, South Carolina
• The Queen Elizabeth Hospital — Adelaide,
• Concord Repatriation General Hospital — Concord,
• Northern Hospital — Melbourne,
• Fiona Stanley Hospital — Murdoch,
• Mater Hospital Brisbane — South Brisbane,
• AZ Maria Middelares — Ghent,
• CHU de Liege — Liège,
• Vitaz — Sint-Niklaas,
• Cliged — Macaé,
• Instituto Mederi de Pesquisa e Saude — Passo Fundo,
• NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul — Porto Alegre,
• INTEGRAL Pesquisa e Ensino — Votuporanga,
• Foothills Hospital — Calgary, Alberta
• Western University & London Health Sciences Centre — London, Ontario
• Hopital du Sacre-Coeur de Montreal — Montreal, Quebec
• Nemocnice Ceske Budejovice a s — České Budějovice,
• Hepato-gastroenterologie HK, s.r.o. — Hradec Králové,
• ISCARE a.s. — Prague,
• CHU Amiens Picardie — Amiens,
• CHU de Clermont Ferrand — Clermont-Ferrand,
• CHRU de Lille Hopital Claude Huriez — Lille,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Crohn's Disease

• A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Birmingham, Alabama
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
• Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. — Blacktown, New South Wales
• Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts

Explore by condition: All Crohn's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.